Citations

Clear

133 citation(s) found for "Fernandes, B C".

21 Feasibility of muscular fitness testing in cardiac rehabilitation with portable movement sensor technology
Scales, Robert , Paul, Frank, Filler, Casey, Song, Zeyu , Moore, Kaitlin , Tomah, Molly, Mariah, McCready, Repp, Kaley, Ivy, Cynthia , Fernandes, Regis, Taylor, Bryan J.

Mayo Clinic

Abstracts | October 6, 2023 | Volume: No volume available | Issue: No issue available | Pages: A12.1-A12

10.1136/heartjnl-2023-bacpr.19 Get It

Referral Sources To A Clinical Exercise Physiology Consultation For Special Populations In A Preventive Cardiology Practice
Scales, Robert , Wright, M.P., Fitz‐Patrick, Dennis, Paul, F. T., Cataldo, Donna, Skeen, Julianne, Fernandes, Regis, Paul, Frank

Mayo Clinic

Medicine & Science in Sports & Exercise | September 26, 2023 | Volume: 55 | Issue: 9S | Pages: 1065-1065

10.1249/01.mss.0000989772.58659.c9 Get It

RNA Sequencing for Solid Tumor Fusion Gene Detection: Proficiency Testing Practice and Performance Comparison
Bridge, Julia A. , Halling, Kevin C. , Moncur, Joel T., Souers, Rhona J., Fernandes, Helen , Roy, Angshumoy , Surrey, Lea F. , Tafe, Laura J. , Vasalos, Patricia, López‐Terrada, Dolores , Hameed, Meera

Mayo Clinic

Archives of Pathology & Laboratory Medicine | August 3, 2023 | Volume: 148 | Issue: 5 | Pages: 538-544

10.5858/arpa.2023-0047-cp | PMID 37535666 Get It

Context Next-generation sequencing–based approaches using RNA have increasingly been used by clinical laboratories for the detection of fusion genes, intragenic rearrangements, and exon-skipping events. Correspondingly, the College of American Pathologists (CAP) has advanced RNA sequencing proficiency testing (PT) to ensure optimal performance of these assays. Objective To report on laboratory performance and practices of RNA sequencing for the detection of fusion genes, intragenic rearrangements, and exon-skipping events using CAP PT data from 8 mailings (2018-A through 2021-B). Design CAP PT RNA sequencing program results from 153 laboratories across 24 proficiency test specimens, interrogating 22 distinct engineered fusion transcripts, were analyzed for correct identification of the fusion event, associated performance variables, and laboratory practices. Results Overall, the 4-year program detection rate (sensitivity) was 95.5% (1486 of 1556 results). False-negative rates were 3.6% (53 of 1463) and 18.3% (17 of 93) for fusion gene and intragenic rearrangement/exon-skipping events, respectively. Only 19 false-positive results were reported among the 8 PT mailings, and most were likely the result of preanalytical or postanalytical errors. There were no practice characteristics (eg, instrumentation, sequencing method) significantly associated with the fusion detection results. Conclusions These data reveal a high overall sensitivity and specificity for fusion gene detection by participating laboratories using clinical RNA sequencing. Performance was comparable across all laboratories, regardless of methodology. The fraction of false-negative results for intragenic rearrangement/exon-skipping events was greater than that for the chimeric fusion genes. False-negative results could not be attributed to any specific practice characteristics.
Gravidez não planejada no Brasil: estudo nacional em oito hospitais universitários
Nilson, Tainá Vieira , Amato, Angélica Amorim , Resende, Ceres Nunes , Primo, Walquíria Quida Salles Pereira , Nomura, Roseli Mieko Yamamoto , Costa, Maria Laura , Opperman, Maria Lúcia, Brock, M. , Trapani, Alberto , Damásio, Lia Cruz Vaz da Costa , Reis, Nadia , Borges, Vera Therezinha Medeiros , Araújo, Ana Cristina Pinheiro Fernandes de , Opperman, Maria Lucia , Brock, Marianna Facchinetti , Trapani, Alberto , Borges, Vera , Araujo, Ana Cristina Pinheiro Fernandes de , Ruano, Rodrigo , Zaconeta, Alberto , Nomura, Roseli , Damasio, Lia , Nilson, Taína Vieira , Ruano, Rodrigo

Mayo Clinic

Revista de Saúde Pública | August 2, 2023 | Volume: 57 | Issue: 1 | Pages: 35

10.11606/s1518-8787.2023057004449 | PMID 37377331 Get It

OBJETIVO: Estimar a prevalência de gestação não planejada (GNP) em oito hospitais públicos universitários, distribuídos nas cinco regiões que compõem o Brasil. MÉTODOS: Análise secundária de um estudo transversal multicêntrico nacional, realizado em oito hospitais universitários públicos, entre 1º de junho e 31 de agosto de 2020, no Brasil. Amostra por conveniência incluindo mulheres que deram à luz em período de sessenta dias consecutivos e atenderam aos seguintes critérios: maiores de 18 anos; idade gestacional acima de 36 semanas no parto; com recém-nascido único e vivo, sem malformações. RESULTADOS: Amostra composta por 1.120 puérperas, das quais 756 (67,5%) declararam que a gravidez não tinha sido programada. A mediana da prevalência de GNP foi de 59,7%. Observou-se diferença significativa na prevalência de GNP entre os hospitais: Campinas (54,8%), Porto Alegre (58,2%), Florianópolis (59%), Teresina (61,2%), Brasília (64,3%), São Paulo (64,6%), Campo Grande (73,9%) e Manaus (95,3%) (p < 0,001). Foram fatores significativamente associados a GNP a idade materna, cor negra, menor renda familiar, maior número de filhos, maior número de pessoas convivendo em casa e não ter parceiro. CONCLUSÃO: na amostra estudada, cerca de dois terços das gestações foram declaradas como não programadas. A prevalência de gestação não planejada teve relação com fatores sociais e demográficos e variou significativamente entre os hospitais universitários avaliados.
Decoding single and paired phonemes using 7T functional MRI
Vitória, Maria Araújo , Fernandes, Francisco Guerreiro , Raemaekers, Mathijs , Boom, Max van den , Ramsey, Nick F.

Mayo Clinic

No container title available | July 28, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3200600/v1 Get It

Abstract Several studies have shown that mouth movements related to the pronunciation of individual phonemes are represented in the sensorimotor cortex. This would theoretically allow for brain computer interfaces that are capable of decoding continuous speech by training classifiers based on the activity in the sensorimotor cortex related to the production of individual phonemes. To address this, we investigated the decodability of trials with individual and paired phonemes (pronounced consecutively with one second interval) using activity in the sensorimotor cortex. Fifteen participants pronounced 3 different phonemes and 3 combinations of two of the same phonemes in a 7T functional MRI experiment. We confirmed that support vector machine (SVM) classification of single and paired phonemes was possible. Importantly, by combining classifiers trained on single phonemes, we were able to classify paired phonemes with an accuracy of 53% (33% chance level), demonstrating that activity of isolated phonemes is present and distinguishable in combined phonemes. A SVM searchlight analysis showed that the phoneme representations are widely distributed in the ventral sensorimotor cortex. These findings provide insights about the neural representations of single and paired phonemes. Furthermore, it supports the notion that speech BCI may be feasible based on machine learning algorithms trained on individual phonemes using intracranial electrode grids.
Does Intra-Uterine Exposure to the Zika Virus Increase Risks of Cognitive Delay at Preschool Ages? Findings from a Zika-Exposed Cohort from Grenada, West Indies
Fernandes, Michelle , Evans, Roberta , Cheng, Mira , Landon, Barbara, Noël, Trevor, Macpherson, C. N. L. , Cudjoe, Nikita, Burgen, Kemi S. , Waechter, Randall , LaBeaud, A. Desirée , Blackmon, Karen

Mayo Clinic

Viruses | May 31, 2023 | Volume: 15 | Issue: 6 | Pages: 1290

10.3390/v15061290 | PMID 37376590 Get It

Maternal infection with Zika virus (ZIKV) is associated with a distinct pattern of birth defects, known as congenital Zika syndrome (CZS). In ZIKV-exposed children without CZS, it is often unclear whether they were protected from in utero infection and neurotropism. Early neurodevelopmental assessment is essential for detecting neurodevelopmental delays (NDDs) and prioritizing at-risk children for early intervention. We compared neurodevelopmental outcomes between ZIKV-exposed and unexposed children at 1, 3 and 4 years to assess exposure-associated NDD risk. A total of 384 mother–child dyads were enrolled during a period of active ZIKV transmission (2016–2017) in Grenada, West Indies. Exposure status was based on laboratory assessment of prenatal and postnatal maternal serum. Neurodevelopment was assessed using the Oxford Neurodevelopment Assessment, the NEPSY® Second Edition and Cardiff Vision Tests, at 12 (n = 66), 36 (n = 58) and 48 (n = 59) months, respectively. There were no differences in NDD rates or vision scores between ZIKV-exposed and unexposed children. Rates of microcephaly at birth (0.88% vs. 0.83%, p = 0.81), and childhood stunting and wasting did not differ between groups. Our results show that Grenadian ZIKV-exposed children, the majority of whom were without microcephaly, had similar neurodevelopmental outcomes to unexposed controls up to at least an age of 4 years.
Cardiometabolic risk factors in young adults diagnosed with acute myocardial infarction
Forey, K F Kevin, Fernandes, R

Mayo Clinic

European Journal of Preventive Cardiology | May 24, 2023 | Volume: 30 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwad125.314 Get It

Abstract Funding Acknowledgements Type of funding sources: None. Background/introduction Morbidity and mortality associated with atherosclerotic cardiovascular diseases are prevalent in young patients. Meanwhile, traditional cardiovascular risk calculators underestimate disease risk in young adults. Purpose To characterize cardiometabolic risk factors and lipid levels in young adults with acute myocardial infarction. Setting: A multicenter, population-based analysis of patients diagnosed at our hospitals in Arizona, as well as our clinic health system spanning Minnesota and Wisconsin. Methods This is a retrospective cohort study including patients 18 to 50 years old diagnosed with acute myocardial infarction from October 1, 2015, to December 31, 2018. Parameters obtained included: Age, sex, ethnicity, body mass index, tobacco use, comorbid medical conditions, fasting blood glucose, hemoglobin A1c, lipid levels, and prescribed lipid-lowering therapy. Results Among 553 young patients diagnosed with acute myocardial infarction, the mean age at the time was 44.4 years, with men accounting for 69.1% of cases. The mean body mass index was 32.2 kg/m2. Hypertension, diabetes mellitus, and tobacco use were present in 64.7%, 25.9%, and 36.2% of patients. Insulin resistance, elevated triglycerides, and low HDL-C were present in 29.8%, 51.0%, and 62.8% of patients, respectively. Approximately 61.3% of patients within this cohort met World Health Organization criteria for diagnosis of metabolic syndrome. Mean LDL-C was 116 mg/dL and mean triglycerides were 190 mg/dL. Statin therapy was prescribed to 92 (16.6%) of patients prior to diagnosis of acute myocardial infarction, whereas 359 (67.3%) of patients met ACC/AHA criteria for lipid-lowering therapy. Within this subgroup receiving statin therapy, the mean serum LDL-C was 101 mg/dl, 26.1% had levels below 70 mg/dL, and 56.5% had LDL-C levels below 100 mg/dL. Thirty-four patients (6.1%) with LDL-C levels greater than 190 mg/dL, and 29 (85.3%) were not on lipid-lowering therapy. Conclusions and Relevance Multiple treatable risk factors were present in most young adults with acute myocardial infarction, including many with LDL-C levels below 100 mg/dL. Being overweight or obese was the most prevalent risk factor, while elevated non-HDL cholesterol was the most common lipid panel abnormality. In addition to known cardiometabolic risk factors, these findings build upon a growing body of evidence implicating triglyceride-rich lipoproteins in non-HDL and remnant cholesterol as an independent risk factor of ASCVD, which were common in this cohort of young patients presenting with myocardial infarction. In this cohort, lipid-lowering therapy was underutilized in young patients with known cardiometabolic risk factors, elevated estimated 10-year ASCVD risk, and individuals with phenotypic Familial Hypercholesterolemia.
C66 PRIMARY RESULTS FROM APOLLO–B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN–MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY
Longhi, Simone , Maurer, Mathew S. , Fontana, Marianna , Grogan, Martha , Gottlieb, Ronald H. , Yu, W. , Sekijima, Yoshiki , White, Matthew T. , Yureneva, Elena, Jay, Patrick Y. , Maurer, Mathew S , Fontana, Marianna , Berk, John L. , Gustafsson, Finn , Simões, M, Fernandes, Fábio Danziato , Gottlieb, R, Kubánek, Miloš , Poulsen, Steen Hvitfeldt , Damy, Thibaud , Diemberger, Igor , Tahara, Nobuhiro , Tang, W.H. Wilson , Obici, Laura , González-Duarte, Alejandra , Vest, J, Gillmore, Julian D.

Mayo Clinic

European Heart Journal Supplements | May 18, 2023 | Volume: 25 | Issue: Supplement_D | Pages: D28-D28

10.1093/eurheartjsupp/suad111.065 Get It

Abstract Introduction Transthyretin–mediated (ATTR) amyloidosis is a progressive, multisystem, fatal disease. Patisiran, an IV RNAi therapeutic, is approved for the treatment of hereditary ATTR amyloidosis with polyneuropathy. The safety and efficacy of patisiran in patients with wild–type or hereditary ATTR amyloidosis with cardiomyopathy (CM) is being investigated in the ongoing APOLLO–B study. Methods Patients were 18–85 yrs old with evidence of cardiac amyloidosis by echocardiography, and ATTR amyloid by tissue biopsy or fulfilling nonbiopsy diagnostic criteria for ATTR amyloidosis with CM. Medical history of heart failure (HF) due to ATTR amyloidosis with ≥1 prior hospitalization or current clinical evidence of HF was required. Patients were randomized 1:1 to patisiran IV 0.3 mg/kg or placebo Q3W for 12 months. The primary endpoint was change from baseline in 6–MWT at Month 12 (M12) with patisiran vs placebo. Results APOLLO–B enrolled 360 patients (patisiran, n=181; placebo, n=179): median age (range), 76.0 (41, 85) yrs; male, 89%; wtATTR, 80%. Baseline characteristics were consistent between patients on tafamidis at baseline (91/360 [25%]) and those who were not. Patisiran achieved a rapid and sustained reduction in serum TTR, irrespective of baseline tafamidis treatment. At M12, patisiran showed a significant benefit vs placebo in 6–MWT (median [95% CI] change from baseline: patisiran, –8.15 [–16.42, 1.50]; placebo, –21.35 [–34.05, –7.52]; HL estimate of median difference: 14.69 [0.69, 28.69]; p=0.0162) and KCCQ–OS (LS mean [SEM] change from baseline: patisiran, 0.300 [1.263]; placebo, –3.408 [1.277]; LS mean [SEM] difference: 3.709 [1.796]; p=0.0397). Consistent benefits with patisiran in 6–MWT and KCCQ–OS were observed across predefined patient subgroups. Time to first event of all–cause hospitalization, urgent HF visit, or death directionally favored patisiran vs placebo (HR [95% CI], 0.839 [0.557, 1.263]), as did all–cause mortality (HR [95% CI], 0.355 [0.110, 1.138]), but all composite outcomes endpoints did not achieve statistical significance over 12 months. Patisiran was well tolerated; most AEs were mild or moderate in severity, and there were no cardiac safety concerns. Conclusions Benefits at 12 months were observed with patisiran vs placebo in functional capacity, and health status and quality of life, in patients with ATTR amyloidosis with CM. The efficacy and safety of patisiran continues to be studied in the APOLLO–B open–label extension.
P352 EXPLORATORY ANALYSES FROM APOLLO–B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY
Kale, Pratibha , Fontana, Marianna , Grogan, Martha , Palacek, T., Hung, R, Puolsen, S, Perfetto, Federico , Yu, W, Sarswat, N., Yureneva, Elena, Jay, Patrick Y. , Cappelli, Francesco , Kale, P, Maurer, Matthew J. , Fontana, Marianna , Fernandes, Fábio Danziato , Taylor, Mark , Hung, R, González-Duarte, Alejandra , Donal, Erwan , Tsujita, Kenichi , White, M, Vest, J, Gillmore, Julian D.

Mayo Clinic

European Heart Journal Supplements | May 18, 2023 | Volume: 25 | Issue: Supplement_D | Pages: D181-D182

10.1093/eurheartjsupp/suad111.425 Get It

Abstract Introduction Transthyretin–mediated (ATTR) amyloidosis is a progressive and fatal disease. Patients with hereditary or wild–type ATTR amyloidosis frequently develop cardiomyopathy (CM). Patisiran, an IV RNAi therapeutic that inhibits synthesis of wt and variant TTR, is approved for the treatment of hATTR amyloidosis with polyneuropathy. Methods In APOLLO–B, patients were 18–85 yrs old with evidence of cardiac amyloidosis by echocardiography, ATTR amyloid deposition on tissue biopsy or fulfilling nonbiopsy diagnostic criteria for ATTR amyloidosis with CM, and had prior hospitalization for heart failure (HF) due to ATTR amyloidosis or clinical evidence of HF. Patients were randomized 1:1 to patisiran IV 0.3 mg/kg or placebo Q3W for 12 months. The primary endpoint was change from baseline in 6–MWT at Month 12 (M12) with patisiran vs placebo. Exploratory parameters at M12 included changes in cardiac biomarkers, echocardiography and Tc scintigraphy. Results APOLLO–B enrolled 360 patients (patisiran, n=181; placebo, n=179): median age, 76.0 yrs; male, 89%; wtATTR, 80%; on tafamidis at baseline, 25%. Patisiran showed a significant benefit compared with placebo in 6–MWT (median [95% CI] change from baseline: patisiran, –8.15 [–16.42, 1.50]; placebo, –21.35 [–34.05, –7.52]; HL estimate of median difference: 14.69 [0.69, 28.69]; p=0.0162). Patisiran demonstrated favorable trends in change from baseline of NT–proBNP (mean fold change ratio [95% CI]: 0.80 [0.73, 0.89]; p=1.825×10–5) and troponin I (mean fold change ratio [95% CI]: 0.87 [0.80, 0.95]; p=0.0011) at M12 vs placebo. Patisiran also demonstrated a trend towards benefit in change from baseline of most evaluated echocardiographic parameters at M12 vs placebo. Patisiran–treated patients evaluable for scintigraphy (n=37) experienced a reduction (37.8%) or no change (62.2%) in Perugini grade at M12 compared with baseline. Among placebo patients (n=28) at M12, none experienced a reduction from baseline in Perugini grade, and 1 (3.6%) increased in grade. Patisiran demonstrated an acceptable safety profile; AEs were mostly mild or moderate in severity, and there were no cardiac safety concerns. Conclusions Exploratory analyses after 12 months provide further evidence for the potential benefit of patisiran treatment on cardiac biomarkers and manifestations of cardiac amyloid involvement in patients with ATTR amyloidosis. The long–term impact of patisiran will be assessed in the ongoing APOLLO–B open–label extension.
Randomized Double-Blind Personalized N-of-1 Clinical Trial to Test the Safety and Potential Efficacy of TJ-68 for Treating Muscle Cramps in Amyotrophic Lateral Sclerosis (ALS): study protocol for a TJ-68 trial.
Mitsumoto, Hiroshi , Oskarsson, Björn , Andrews, Howard A., Jang, Grace E. , Shah, Jaimin , Fernandes, Joseph Americo, McElhiney, Martin , Santella, Regina M. , Oskarsson, Björn , Cheung, Ken , Andrews, Jinsy , Fernandes, J. Americo

Mayo Clinic

No container title available | January 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2402049/v1 Get It

Abstract Introduction/Aims: Muscle cramps are a common and often disabling symptom in Amyotrophic Lateral Sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in this patient population may sustain quality of life longer. A traditional Japanese medicine, shakuyakukanzoto (TJ-68) is widely prescribed in Japan for managing muscle cramps in a variety of conditions. The Japanese ALS Management Guideline mentions TJ-68 for difficult muscle cramps in ALS. Therefore, this clinical trial is designed to test the safety and efficacy of TJ-68 in participants with ALS reporting serious muscle cramps using a personalized N-of-1 approach. If successful, we can introduce TJ-68 for muscle cramps in ALS to Western medicine. Methods: With FDA-IND approval, we are conducting a two-site, double-blind, randomized personalized N-of-1 early clinical trial with TJ-68. At least 22 participants with ALS and daily muscle cramps will receive drug or placebo for 2 weeks (one treatment period) followed by a 1-week washout in a four-period cross-over design. While the primary objective is to evaluate the safety of TJ-68, the study was sized to detect a one-point shift on the Columbia Muscle Cramp Scale (MCS) item #5 with 85% power under a four-period crossover design.The secondary assessment includes the full MCS score, a Cramp Diary, Clinical Global Impression of Changes, Goal Attainment Scale, quality of life scale and ALS functional rating scale-revised (ALSFRS-R). Discussion: The study is underway. A personalized N-of-1 trial design is an efficient approach to testing medications that alleviate MCS in rare disorders. If TJ-68 proves safe and efficacious, we will work to introduce this product to Western medicine for treatment of patients with ALS and disabling muscle cramps. Trial Registration: This clinical trial has been registered with ClinicalTrials.gov (NCT04998305).